overall survival

Open Access
Prognostic Factors of Extramammary Paget’s Disease: A Retrospective Study at a Medical Center in Taiwan
HSUEH-FEN NI, JIAN-RI LI, SHIAN-SHIANG WANG, SHENG-CHUN HUNG, CHENG-KUANG YANG, CHUAN-SHU CHEN and KUN-YUAN CHIU

In Vivo November 2023, 37 (6) 2786-2791; DOI: https://doi.org/10.21873/invivo.13390
Open Access
Adjuvant Radiotherapy for Major Salivary Gland Malignancies: Impact on Locoregional Control and Survival Outcomes
ATSUTO KATANO and HIDEOMI YAMASHITA

In Vivo November 2023, 37 (6) 2792-2795; DOI: https://doi.org/10.21873/invivo.13391
Open Access
Atezolizumab Monotherapy for Non-small Cell Lung Cancer Patients: An Observational Study in Ibaraki Group (ATTENTION-IBARAKI)
SHINICHIRO OKAUCHI, GEN OHARA, TOSHIHIRO SHIOZAWA, HIROKO WATANABE, TAKESHI NUMATA, RYOTA NAKAMURA, TOMOHIRO TAMURA, NORIHIRO KIKUCHI, KUNIHIKO MIYAZAKI, SHIGEN HAYASHI, HIROFUMI SAKURAI, TAKAAKI YAMASHITA, KOICHI KURISHIMA, MASAHARU INAGAKI, TAKEO ENDO, HIROICHI ISHIKAWA, TAKAYUKI KABURAGI, HIROAKI SATOH, TORU SAKAMOTO and NOBUYUKI HIZAWA

In Vivo September 2023, 37 (5) 2203-2209; DOI: https://doi.org/10.21873/invivo.13320
Open Access
Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer
JIRI BLAZEK, PETR HOSEK, KAROLINA HRABCOVA, MONIKA BRATOVA, JURAJ KULTAN, MICHAL HRNCIARIK, MARKETA CERNOVSKA, PETRA ZEMANOVA, JANA KREJCI, LEONA KOUBKOVA, MAREK STASTNY and MARTIN SVATON

In Vivo September 2023, 37 (5) 2229-2236; DOI: https://doi.org/10.21873/invivo.13324
Open Access
Overall Survival Following Anastomotic Leakage After Surgery for Carcinoma of the Esophagus and Gastroesophageal Junction: A Systematic Review
MARCO PACE, ANDREA MINERVINI, MARTA GOGLIA, MATTEO CINQUEPALMI, GIOVANNI MOSCHETTA, LAURA ANTOLINO, FRANCESCO D’ANGELO, STEFANO VALABREGA, NICCOLO PETRUCCIANI, GIAMMAURO BERARDI and PAOLO AURELLO

In Vivo July 2023, 37 (4) 1423-1431; DOI: https://doi.org/10.21873/invivo.13226
Open Access
Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases
VACLAV KUBES, LEOS KREN, FILIP SOKOL, JOZEF MICHALKA, JAN MUZIK, TOMAS ARPAS, ZDENKA KRENOVA and ZDENEK KRAL

In Vivo July 2023, 37 (4) 1735-1742; DOI: https://doi.org/10.21873/invivo.13261
Open Access
Early Palliative Care Improves Overall Survival in Patients With Lymphoma: A Single-institution Retrospective Study
MISAKI MORISAKU, KAORI ITO, TATSUKI SHIMOMURA, SHOKO MAEDA, MAIKO MORI, SEIRA TOYOSATO, YOSUKE ANDO, TAKENAO KOSEKI, MASAMI KAWAHARA, AKIHIRO TOMITA and SHIGEKI YAMADA

In Vivo November 2022, 36 (6) 2910-2917; DOI: https://doi.org/10.21873/invivo.13032
Open Access
Interstitial Brachytherapy of the Liver for Renal Cell Carcinoma: ADC Measurements Do Not Predict Overall Survival
MAXIMILIAN THORMANN, FRANZISKA HEITMANN, VANESSA WROBEL, CHRISTINE MARCH, MACIEJ PECH, ALEXEY SUROV, ROBERT DAMM and JAZAN OMARI

In Vivo November 2022, 36 (6) 2945-2951; DOI: https://doi.org/10.21873/invivo.13037
Open Access
Mode of Referral of Ovarian Cancer Patients: Does it Alter Treatment and Survival?
ANAS BARAKAT, AEMN ISMAIL, QUENTIN DAVIES and SUPRATIK CHATTOPADHYAY

In Vivo July 2022, 36 (4) 1834-1840; DOI: https://doi.org/10.21873/invivo.12900
Open Access
Survival Outcomes With Reduced Doses of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
JUHUN LEE, JONG MI KIM, YOON HEE LEE, GUN OH CHONG and DAE GY HONG

In Vivo July 2022, 36 (4) 1868-1874; DOI: https://doi.org/10.21873/invivo.12905

Main menu

User menu

Search

overall survival

Pages